Ultragenyx Pharmaceutical

Rosen Law Firm notifies $RARE investors of securities class action alleging materially false statements about setrusumab efficacy in Phase III trials, with April 6, 2026 lead plaintiff deadline.

Securities class action filed against RARE over alleged false statements regarding Phase III clinical trials for setrusumab. Claim deadline April 6, 2026.

Rosen Law Firm files securities class action against Ultragenyx Pharmaceutical ($RARE) alleging false statements about setrusumab efficacy in clinical trials.

Securities class action filed against $RARE for allegedly misrepresenting setrusumab efficacy data. Investors may claim damages; lead plaintiff deadline April 6, 2026.

Securities class action filed against $RARE over alleged misstatements about setrusumab drug efficacy. Failed clinical trials triggered 25-42% stock declines. Investor deadline: April 6, 2026.

Class action lawsuit filed against $UGXY alleging securities fraud over misleading setrusumab trial data and OI patient safety disclosures.

Ultragenyx faces a securities class action alleging misrepresentations about its setrusumab drug's efficacy for osteogenesis imperfecta. Affected investors have until April 6, 2026 to serve as lead plaintiff.

Law firm Kahn Swick & Foti files class action against $UGXX over failed Phase 3 trial for rare bone disease drug setrusumab. Investors can apply as lead plaintiffs by April 6.

Class action lawsuit filed against $UGXY alleging securities fraud related to setrusumab clinical trial data. Investors from August 2023 to December 2025 eligible.

Portnoy Law Firm filed securities class action against Ultragenyx Pharmaceutical, alleging the company made false statements about investigational drug setrusumab and concealed material clinical trial risks.

Ultragenyx faces securities lawsuit alleging false claims about drug setrusumab for bone disease. Investors have until April 6, 2026 deadline to join class action.

Rosen Law Firm sues Ultragenyx for securities fraud, alleging executives misrepresented drug efficacy. Investors who bought stock August 2023-December 2025 can claim damages by April 6, 2026 deadline.

Ultragenyx faces class action lawsuit alleging false statements about its osteogenesis imperfecta drug's efficacy after Phase III trial failed to meet primary endpoint.